Mr. Lee has been a member of our Board of Directors since March 2018. Since January 2003, he has been a general partner of Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies. Previously he was president of Pappas Capital, LLC (formerly A. M. Pappas & Associates, LLC), following 29 years with Ernst & Young LLP, where he was most recently managing director of the firm’s health sciences corporate finance group. Mr. Lee currently serves on the board of directors of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Previously, he served on the boards of several private and public companies, including Abgenix, Inc. (NASDAQ: ABGX, acquired by Amgen Inc. (NASDAQ: AMGN)), CV Therapeutics, Inc. (NASDAQ: CVTX, acquired by Gilead Sciences, Inc. (NASDAQ: GILD)), Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH, acquired by Merck & Co., Inc. NYSE: MRK), Maxygen, Inc. (NASDAQ: MAXY, dissolved), OSI Pharmaceuticals, Inc. (NASDAQ: OSIP, acquired by Astellas Pharma Inc. (OTC: ALPMY)), Old API Wind-down Ltd. (f/k/a Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), which began voluntary bankruptcy proceedings in Canada and filed for Chapter 11 bankruptcy in the United States in August 2018). Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill.
What is Kenneth B. Lee, Jr.'s net worth?
The estimated net worth of Kenneth B. Lee, Jr. is at least $11,066.10 as of June 11th, 2021. Mr. Lee, Jr. owns 21,359 shares of Eyenovia stock worth more than $11,066 as of November 5th. This net worth estimate does not reflect any other assets that Mr. Lee, Jr. may own. Learn More about Kenneth B. Lee, Jr.'s net worth.
How do I contact Kenneth B. Lee, Jr.?
Has Kenneth B. Lee, Jr. been buying or selling shares of Eyenovia?
Kenneth B. Lee, Jr. has not been actively trading shares of Eyenovia during the last ninety days. Most recently, on Monday, June 14th, Kenneth B. Lee, Jr. bought 2,000 shares of Eyenovia stock. The stock was acquired at an average cost of $5.47 per share, with a total value of $10,940.00. Following the completion of the transaction, the director now directly owns 21,359 shares of the company's stock, valued at $116,833.73. Learn More on Kenneth B. Lee, Jr.'s trading history.
Who are Eyenovia's active insiders?
Are insiders buying or selling shares of Eyenovia?
In the last twelve months, Eyenovia insiders bought shares 7 times. They purchased a total of 1,757,829 shares worth more than $1,225,659.84. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company.
Learn More about insider trades at Eyenovia. Information on this page was last updated on 8/28/2024.
